| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Familial papillary thyroid microcarcinoma: a new clinical entity.
|
Lancet
|
1999
|
1.98
|
|
2
|
The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article.
|
Amino Acids
|
2004
|
1.44
|
|
3
|
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1.
|
Cell Death Dis
|
2012
|
1.40
|
|
4
|
Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.
|
Curr Drug Targets
|
2005
|
1.21
|
|
5
|
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro.
|
Br J Cancer
|
2003
|
1.21
|
|
6
|
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.
|
Cell Death Dis
|
2011
|
1.18
|
|
7
|
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways.
|
Curr Drug Targets
|
2005
|
1.10
|
|
8
|
Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells.
|
Cell Prolif
|
2012
|
1.09
|
|
9
|
WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors.
|
Oncol Rep
|
2010
|
1.09
|
|
10
|
Acetylation of proteins as novel target for antitumor therapy: review article.
|
Amino Acids
|
2004
|
1.08
|
|
11
|
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy.
|
Cell Death Dis
|
2012
|
1.05
|
|
12
|
Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series.
|
Thyroid
|
2002
|
1.04
|
|
13
|
C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A.
|
Cell Death Differ
|
2007
|
1.01
|
|
14
|
Current approaches and perspectives in the therapy of medullary thyroid carcinoma.
|
Cancer
|
2001
|
0.97
|
|
15
|
Homology modelling of the human eukaryotic initiation factor 5A (eIF-5A).
|
Protein Eng
|
2001
|
0.97
|
|
16
|
Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.
|
Curr Cancer Drug Targets
|
2012
|
0.97
|
|
17
|
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.
|
Int J Cancer
|
2011
|
0.97
|
|
18
|
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
|
Int J Pharm
|
2010
|
0.97
|
|
19
|
Deregulation of HOX B13 expression in urinary bladder cancer progression.
|
Curr Med Chem
|
2013
|
0.96
|
|
20
|
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.
|
Cell Death Dis
|
2013
|
0.95
|
|
21
|
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.
|
Br J Cancer
|
2001
|
0.94
|
|
22
|
Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma.
|
J Clin Endocrinol Metab
|
2000
|
0.93
|
|
23
|
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
|
J Cell Mol Med
|
2012
|
0.92
|
|
24
|
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.
|
Br J Cancer
|
2012
|
0.88
|
|
25
|
Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects.
|
Curr Cancer Drug Targets
|
2009
|
0.87
|
|
26
|
Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells.
|
Br J Haematol
|
1998
|
0.86
|
|
27
|
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells.
|
Cancer Res
|
1991
|
0.86
|
|
28
|
The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
|
J Exp Clin Cancer Res
|
2007
|
0.86
|
|
29
|
Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer.
|
Br J Cancer
|
2005
|
0.86
|
|
30
|
Denosumab: the era of targeted therapies in bone metastatic diseases.
|
Curr Cancer Drug Targets
|
2009
|
0.86
|
|
31
|
P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia.
|
Oncol Rep
|
2004
|
0.86
|
|
32
|
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
|
Cell Death Dis
|
2013
|
0.85
|
|
33
|
The role of E-cadherin down-regulation in oral cancer: CDH1 gene expression and epigenetic blockage.
|
Curr Cancer Drug Targets
|
2014
|
0.84
|
|
34
|
Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy.
|
Curr Cancer Drug Targets
|
2009
|
0.83
|
|
35
|
Possible antioxidant role of SPA therapy with chlorine-sulphur-bicarbonate mineral water.
|
Amino Acids
|
2008
|
0.83
|
|
36
|
Theophylline administration markedly reduces hepatic and pulmonary implantation of B16-F10 melanoma cells in mice.
|
Melanoma Res
|
2000
|
0.83
|
|
37
|
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice.
|
Ann Oncol
|
2010
|
0.83
|
|
38
|
Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the beta 1 integrin profile of cultured human tumor cells.
|
Anticancer Drugs
|
1995
|
0.83
|
|
39
|
Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
|
Int J Oncol
|
2005
|
0.82
|
|
40
|
Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
|
Oncol Rep
|
2008
|
0.82
|
|
41
|
Daily low-dose subcutaneous recombinant interleukin-2 by alternate weekly administration: antitumor activity and immunomodulatory effects.
|
Am J Clin Oncol
|
1998
|
0.82
|
|
42
|
Adenylate cyclase/cAMP pathway downmodulation counteracts apoptosis induced by IFN-alpha in human epidermoid cancer cells.
|
J Interferon Cytokine Res
|
2007
|
0.81
|
|
43
|
Raf kinases mediate the phosphorylation of eukaryotic translation elongation factor 1A and regulate its stability in eukaryotic cells.
|
Cell Death Dis
|
2012
|
0.81
|
|
44
|
Protein-polyamine conjugation by transglutaminase in cancer cell differentiation: review article.
|
Amino Acids
|
2004
|
0.81
|
|
45
|
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial.
|
BMC Cancer
|
2006
|
0.81
|
|
46
|
Tissue transglutaminase expression affects hypusine metabolism in BALB/c 3T3 cells.
|
FEBS Lett
|
1998
|
0.81
|
|
47
|
Concomitant occurrence of a primary renal NHL and of a papillary urothelial ureter cancer.
|
J Exp Clin Cancer Res
|
2007
|
0.81
|
|
48
|
Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cells.
|
Cancer Biol Ther
|
2015
|
0.80
|
|
49
|
γ-Tocopherol inhibits human prostate cancer cell proliferation by up-regulation of transglutaminase 2 and down-regulation of cyclins.
|
Amino Acids
|
2012
|
0.80
|
|
50
|
Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
|
Cancer Immunol Immunother
|
1992
|
0.79
|
|
51
|
Extracellular adenosine 5' triphosphate involvement in the death of LAK-engaged human tumor cells via P2X-receptor activation.
|
Immunol Lett
|
1997
|
0.79
|
|
52
|
A hitherto unreported high incidence of zoledronic acid-induced acute phase reaction in patients with cancer treatment-induced bone loss.
|
Ann Oncol
|
2006
|
0.79
|
|
53
|
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
|
Br J Cancer
|
2004
|
0.79
|
|
54
|
Bovine serum amine oxidase and spm potentiate docetaxel and interferon-alpha effects in inducing apoptosis on human cancer cells through the generation of oxidative stress.
|
Biochim Biophys Acta
|
2008
|
0.79
|
|
55
|
High-dose recombinant interleukin-2/verapamil combination in advanced cancer.
|
Eur J Cancer
|
1996
|
0.78
|
|
56
|
Mediastinal images resembling thymus following 131-I treatment for thyroid cancer.
|
Monaldi Arch Chest Dis
|
2005
|
0.78
|
|
57
|
Pharmacological modulation of peptide growth factor receptor expression on tumor cells as a basis for cancer therapy.
|
Anticancer Drugs
|
1994
|
0.78
|
|
58
|
Role of the FAD-dependent polyamine oxidase in the selective formation of N(1),N(8)-bis(gamma-glutamyl)spermidine protein cross-links(1).
|
Biochem Soc Trans
|
2007
|
0.77
|
|
59
|
Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.
|
J Biomed Nanotechnol
|
2016
|
0.77
|
|
60
|
Structural organization of the human eukaryotic initiation factor 5A precursor and its site-directed variant Lys50-->Arg.
|
Amino Acids
|
1999
|
0.77
|
|
61
|
[Evaluation in vitro of the cardiotoxic effects of 5-fluorouracil for the prevention of cardiovascular damage in health workers occupationally exposed].
|
G Ital Med Lav Ergon
|
2013
|
0.77
|
|
62
|
Tumour cell resistance to non-MHC-restricted lymphocytes: molecular mechanisms and clinical implications.
|
Cancer Immunol Immunother
|
1998
|
0.77
|
|
63
|
Phorbol 12-myristate 13-acetate (pma) induces neuroendocrine-like differentiation and reverses Doxorubicin-resistance of human colon-carcinoma cells in-vitro.
|
Int J Oncol
|
1994
|
0.77
|
|
64
|
Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchimal tumors of the gastrointestinal tract.
|
Amino Acids
|
2007
|
0.77
|
|
65
|
The role of somatostatin receptors in the medical treatment of acromegaly.
|
Dig Liver Dis
|
2004
|
0.77
|
|
66
|
Percutaneous ethanol injection of autonomous thyroid nodules with a volume larger than 40 ml: three years of follow-up.
|
Clin Radiol
|
2001
|
0.77
|
|
67
|
Evaluation of the efficacy of potential antineoplastic drugs on tumour metastasis by a computer-assisted image analysis.
|
Eur J Cancer
|
2000
|
0.77
|
|
68
|
Cardiovascular monitoring of drug-resistant lymphoma patients treated with epoch chemotherapy plus high-dose verapamil in continuous-infusion.
|
Oncol Rep
|
1994
|
0.76
|
|
69
|
Anticancer drugs and hyperthermia enhance cytotoxicity induced by polyamine enzymatic oxidation products.
|
Amino Acids
|
2007
|
0.76
|
|
70
|
Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide.
|
Eur J Cancer Care (Engl)
|
2009
|
0.76
|
|
71
|
Cytosine arabinoside (Ara-C) plus alpha-interferon (alpha IFN) determine prolonged complete remissions in patients with aggressive non-Hodgkin's lymphoma partially responsive to first-line doxorubicin-containing regimens.
|
Br J Haematol
|
1994
|
0.75
|
|
72
|
8-Cl-cAMP antagonizes mitogen-activated protein kinase activation and cell growth stimulation induced by epidermal growth factor.
|
Br J Cancer
|
1999
|
0.75
|
|
73
|
Impairment of the metastatic activity of melanoma cells by transglutaminase-catalyzed incorporation of polyamines into laminin and Matrigel.
|
Amino Acids
|
2007
|
0.75
|
|
74
|
Transmembrane ion flux modifiers verapamil and ouabain modulate cytotoxic effects of extracellular ATP on human tumor-cells in-vitro.
|
Int J Oncol
|
1993
|
0.75
|
|
75
|
Phase II studies of anticancer chemotherapy: indirect evidence of poor quality.
|
Ann Oncol
|
2006
|
0.75
|
|
76
|
Editorial: target therapy in brain tumours and metastases.
|
Curr Cancer Drug Targets
|
2012
|
0.75
|
|
77
|
A liver angioma colonized by colon cancer cells in a patient with two primitive localizations by colon adenocarcinoma: biologic, diagnostic and therapeutic implications.
|
Ann Oncol
|
2005
|
0.75
|
|
78
|
Small tumor of the medial breast presenting with a contralateral lymph node involvement detected on positron emission tomography scan.
|
Ann Oncol
|
2007
|
0.75
|
|
79
|
A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology.
|
Ann Oncol
|
2007
|
0.75
|
|
80
|
CD10/common acute lymphoblastic leukemia-associated antigen and adhesion factor expression is predictive for lymphokine-activated killing sensitivity of adult B-lineage acute lymphoblastic leukemia.
|
Year Immunol
|
1993
|
0.75
|
|
81
|
Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells.
|
Clin Cancer Res
|
1995
|
0.75
|
|
82
|
Maintenance therapy with recombinant interferon alpha-2B (alpha IFN) in prognostically unfavourable aggressive non-Hodgkin's lymphomas (NHL).
|
Oncol Rep
|
1996
|
0.75
|
|
83
|
Mitoxantrone, Etoposide and bleomycin (meb) chemotherapy in non-hodgkins-lymphoma patients non-elegible for standard cyclophosphamide, Doxorubicin, vincristine and prednisone (chop) combination.
|
Oncol Rep
|
1995
|
0.75
|
|
84
|
Differential sensitivity to non-major histocompatibility complex-restricted recombinant interleukin 2-activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or protein kinase A subunits.
|
Clin Cancer Res
|
1996
|
0.75
|
|
85
|
A case of clear renal cell cancer associated to meningioma and verrucous carcinoma of frontal region in an old patient.
|
J Exp Clin Cancer Res
|
2007
|
0.75
|